Enterprise Value
667.7M
Cash
127.6M
Avg Qtr Burn
-17.67M
Short % of Float
11.43%
Insider Ownership
1.74%
Institutional Own.
56.10%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
XPHOZAH (Tenapanor) (Phosphate Absorption Inhibitor) Details Electrolyte disorder, Hyperphosphatemia, Kidney disease, Chronic kidney disease | Approved Quarterly sales | |
Tenapanor (Ibsrela) (NHE3 sodium transport inhibitor) Details Irritable bowel syndrome, Constipation | Approved Quarterly sales | |
RDX013 Details Hyperkalemia | Phase 2 Update |